Highlighting the interaction between immunomodulatory properties of mesenchymal stem cells and signaling pathways contribute to Graft Versus Host Disease management

2022 ◽  
pp. 101524
Author(s):  
Reza Mirfakhraie ◽  
Maria Tavakoli Ardakani ◽  
Abbas Hajifathali ◽  
Samira Karami ◽  
Mohammad Reza Moshari ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Disease Management ◽  
Signaling Pathways ◽  
Graft Versus Host Disease ◽  
Host Disease ◽  
Graft Versus Host ◽  
Immunomodulatory Properties

scholarly journals Immunomodulatory effect of mesenchymal stem cells

2011 ◽  
Vol 9 (2) ◽  
pp. 224-228 ◽  
Author(s):  
Luciana Cavalheiro Marti ◽  
Andreza Alice Feitosa Ribeiro ◽  
Nelson Hamerschlak
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Graft Versus Host Disease ◽  
Plasma Cells ◽  
Adult Population ◽  
Cell Types ◽  
Host Disease ◽  
Graft Versus Host ◽  
Immunomodulatory Properties ◽  
Acute Graft

Mesenchymal stem cells represent an adult population of nonhematopoietic cells, which can differentiate into a variety of cell types such as osteocytes, chondrocytes, adipocytes, and myocytes. They display immunomodulatory properties that have led to the consideration of their use for the inhibition of immune responses. In this context, mesenchymal stem cells efficiently inhibit maturation, cytokine production, and the T cell stimulatory capacity of dendritic cells. They also can impair proliferation, cytokine secretion, and cytotoxic potential of T lymphocytes. Moreover, mesenchymal stem cells are able to inhibit the differentiation of B cells to plasma cells by inhibiting their capacity to produce antibodies. A variety of animal models confirm the immunomodulatory properties of mesenchymal stem cells. Clinical studies including patients with severe acute graft-versus-host disease have revealed that the administration of mesenchymal stem cells results in significant clinical responses. Therefore, mesenchymal stem cells improve acute graft-versus-host disease and represent a promising candidate for the prevention and treatment of immune-mediated diseases, due to their immunomodulatory capability and their low immunogenicity.

scholarly journals Small‐sized mesenchymal stem cells with high glutathione dynamics show improved therapeutic potency in graft‐versus‐host disease

2021 ◽  
Vol 11 (7) ◽  
Author(s):  
Jisun Lim ◽  
Jinbeom Heo ◽  
Hwan Yeul Yu ◽  
HongDuck Yun ◽  
Seungun Lee ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Graft Versus Host Disease ◽  
Host Disease ◽  
Graft Versus Host

Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells

The Lancet ◽  
2004 ◽  
Vol 363 (9419) ◽  
pp. 1439-1441 ◽  
Author(s):  
Katarina Le Blanc ◽  
Ida Rasmusson ◽  
Berit Sundberg ◽  
Cecilia Götherström ◽  
Moustapha Hassan ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Graft Versus Host Disease ◽  
Third Party ◽  
Host Disease ◽  
Graft Versus Host ◽  
Acute Graft

Mesenchymal Stem Cells Attenuate Rat Graft-Versus-Host Disease

2014 ◽  
pp. 341-353 ◽  
Author(s):  
Masayuki Fujino ◽  
Ping Zhu ◽  
Yusuke Kitazawa ◽  
Ji-Mei Chen ◽  
Jian Zhuang ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Graft Versus Host Disease ◽  
Host Disease ◽  
Graft Versus Host

scholarly journals Glutathione dynamics determine the therapeutic efficacy of mesenchymal stem cells for graft-versus-host disease via CREB1-NRF2 pathway

2020 ◽  
Vol 6 (16) ◽  
pp. eaba1334 ◽  
Author(s):  
Jisun Lim ◽  
Jinbeom Heo ◽  
Hyein Ju ◽  
Ji-Woong Shin ◽  
YongHwan Kim ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Graft Versus Host Disease ◽  
Target Genes ◽  
Cellular Immunotherapy ◽  
Humanized Mouse Model ◽  
Host Disease ◽  
Nrf2 Pathway ◽  
Graft Versus Host ◽  
Nonprotein Thiol

Glutathione (GSH), the most abundant nonprotein thiol functioning as an antioxidant, plays critical roles in maintaining the core functions of mesenchymal stem cells (MSCs), which are used as a cellular immunotherapy for graft-versus-host disease (GVHD). However, the role of GSH dynamics in MSCs remains elusive. Genome-wide gene expression profiling and high-throughput live-cell imaging assays revealed that CREB1 enforced the GSH-recovering capacity (GRC) of MSCs through NRF2 by directly up-regulating NRF2 target genes responsible for GSH synthesis and redox cycling. MSCs with enhanced GSH levels and GRC mediated by CREB1-NRF2 have improved self-renewal, migratory, anti-inflammatory, and T cell suppression capacities. Administration of MSCs overexpressing CREB1-NRF2 target genes alleviated GVHD in a humanized mouse model, resulting in improved survival, decreased weight loss, and reduced histopathologic damages in GVHD target organs. Collectively, these findings demonstrate the molecular and functional importance of the CREB1-NRF2 pathway in maintaining MSC GSH dynamics, determining therapeutic outcomes for GVHD treatment.

Sign in / Sign up

Export Citation Format

Share Document